FDA Extends Review Period for Anticipated Alzheimer ' s Drug FDA Extends Review Period for Anticipated Alzheimer ' s Drug

The FDA has extended the review period for aducanumab, the investigational amyloid-clearing treatment for Alzheimer ' s disease, by 3 months, the drug ' s manufacturers have announced.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news